SK Pharmteco Gathers Industry Leaders to Debate Future of Pharmaceutical Manufacturing
Event summary
- SK Pharmteco hosts one-day symposium on April 8, 2026, in Cambridge, MA, focusing on continuous manufacturing and scalable technologies.
- Keynote by Jason E. Hein, Ph.D., on data-driven decision-making and automation in process development.
- Panel includes executives from Gilead, Antheia, Eli Lilly, Amgen, and Praxis Precision Medicines.
- Event features technical sessions on synthetic biology, yeast metabolic engineering, and small-molecule scale-up.
The big picture
SK Pharmteco's symposium underscores the industry's push toward digital integration and automation in pharmaceutical manufacturing. As biopharmaceutical companies face pressure to accelerate development timelines, the event highlights the strategic importance of scalable technologies and continuous manufacturing. The participation of key players like Gilead and Eli Lilly signals growing industry collaboration in shaping the 'factory of the future.'
What we're watching
- Technological Adoption
- How the pace of continuous manufacturing adoption will impact SK Pharmteco's competitive positioning.
- Industry Collaboration
- Whether partnerships with major pharma players will drive SK Pharmteco's growth in advanced processing.
- Regulatory Shifts
- The extent to which regulatory changes will influence the scalability of new manufacturing technologies.
Related topics